Aduhelm is the first drug to be approved by the FDA that claims to treat Alzheimer's disease rather ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThis study aimed to review timelines and use of financial agreements for products being appraised.
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreWhat is the future of precision medicine in the EU? The field of precision medicine is a complex are...
Read moreThe law provides a legal framework for the automatic substitution of biosimilars at the level of the...
Read moreCanadians pay too much for prescription drugs – and that means far too many go without the medicin...
Read moreInitially NICE rejected Illumetri for not being cost-effective, but a new negotiated price means th...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read more